Experienced Team with Strong Relationships and Networks

Robert S. Vaters, Partner (47)

Mr. Vaters was Executive Vice President of INAMED Corporation from 2002 to March 2006. He was a senior member of the management team that created over $2.8 billion of shareholder value in four years.  As Executive Vice President, Strategy and Corporate Development and Chief Financial Officer, Mr. Vaters was responsible for strategy, corporate development, mergers and acquisitions, corporate finance, tax, treasury, investor relations, and financial reporting. During Mr. Vaters' tenure at INAMED Corporation, sales increased from $240 million to $438 million, profits more than doubled and INAMED Corporation was sold to Allergan Inc. for $3.2 billion.  From 2000-2001, Mr. Vaters was an Executive Vice President, Chief Operating and Chief Financial Officer of ARBINET THEEXCHANGE, Inc., a leading telecommunications bandwidth exchange. Mr. Vaters led several financings, a $20 million ERP installation and filed an S-1 initial public offering while at ARBINET. From 1996-2000, Mr. Vaters was Executive Vice President, Chief Financial Officer of Premiere Technologies, Inc. and a predecessor company, Xpedite Systems, Inc. While at Premiere Technologies, Mr. Vaters ran their $75 million Asia Pacific business based in Sydney, Australia which was a top performing business for Premiere. From 1993-1996, Mr. Vaters was Senior Vice President and Treasurer of Young and Rubicam, Inc. Mr. Vaters attended Harvard Business School’s Executive Education Program and earned a MBA from Fordham University and a BA from St. Francis College. Mr. Vaters is the Chairman of the Board of Directors of Applied NeuroSolutions (NASDAQ: APNS), a biotechnology company specializing in the diagnosis and treatment of Alzheimer’s disease.

Vicente Trelles, Partner (51)

Mr. Trelles was Executive Vice President of INAMED Corporation from 2001 to March 2006. He was a senior member of the management team that created over $2.8 billion of shareholder value in four years.  During that period sales increased from $240 million to $438 million and earnings more than doubled.  As Executive Vice President and Chief Operations Officer, Mr. Trelles was responsible for managing INAMED’s global operations including product development, quality systems, manufacturing, supply chain, regulatory compliance, and key strategic business partnerships. Mr. Trelles was responsible for 600 employees worldwide and manufacturing facilities in Ireland, California and Costa Rica. He has spent 24 years within the medical device and pharmaceutical industries managing global operations at INAMED, Allergan and Baxter Healthcare. From 1999-2001, Mr. Trelles was the Chief Operating Officer of McGhan Medical (a wholly owned subsidiary of INAMED) where he managed product development, clinical research, quality, regulatory affairs and compliance, manufacturing, supply chain information technology and distribution functions. From 1990-1999, Mr. Trelles was a senior operating executive at Allergan, Inc. including VP, Worldwide Surgical Operations, Vice President, Europe Operations and a General Manager and Vice President of Manufacturing for their Contact Lens Business. From 1981-1990, Mr. Trelles was a senior operating executive at Baxter Health Care Corporation and American Hospital Supply including General Manager at its V. Mueller Division in Puerto Rico. Mr. Trelles received a BS in Industrial Engineering from University of Puerto Rico.

James A. Breckenridge, Partner (41)

Mr. Breckenridge joined UBS Capital Americas upon its formation in 1993. Since 1997, Mr. Breckenridge has led UBS Capital Americas’ investment efforts in the healthcare and life science sectors. Mr. Breckenridge originated, executed and led $60 million of investments in medical device / medical technology and bio-pharmaceutical investments. Including non-healthcare investments, Mr. Breckenridge has overseen and participated in private equity transactions aggregating over $2 billion in total value since 1993 and UBS Capital Americas’ equity investments of $195 million. Mr. Breckenridge led UBS Capital Americas’ investment in Avail Medical Products, Inc.  From 1988-1991, he worked in the equity research department of Kidder, Peabody & Co., Inc. following the food, beverage and tobacco industries. Mr. Breckenridge earned a MBA from Columbia University and a BA from Colgate University.Mr. Breckenridge serves as a Director of Avail Medical Products, Inc.